TY - JOUR
T1 - Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis
T2 - case report
AU - Holmstroem, Rikke Boedker
AU - Dahl, Emilie Kristine
AU - Helms, Morten
AU - Nielsen, Henrik Vedel
AU - Andersen, Janne Bayer
AU - Bjerrum, Jacob Tveiten
AU - Svane, Inge Marie
AU - Ellebaek, Eva
AU - Seidelin, Jakob Benedict
N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022/12
Y1 - 2022/12
N2 - BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.
AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.
KW - Humans
KW - Fecal Microbiota Transplantation/adverse effects
KW - Antineoplastic Agents, Immunological/adverse effects
KW - Enterocolitis/chemically induced
KW - Colitis/therapy
UR - http://www.scopus.com/inward/record.url?scp=85164528075&partnerID=8YFLogxK
U2 - 10.1136/bmjgast-2022-000989
DO - 10.1136/bmjgast-2022-000989
M3 - Journal article
C2 - 36581371
SN - 2054-4774
VL - 9
JO - BMJ Open Gastroenterology
JF - BMJ Open Gastroenterology
IS - 1
M1 - e000989
ER -